Sector News

SynteractHCR taps industry veteran Steve Powell as new CEO

July 18, 2017
Life sciences

Having served as senior-level executive at such clinical service providers as Exco InTouch and PRA Health Sciences, Steve Powell has taken the helm at SynteractHCR, succeeding Wendel Barr, the CRO’s CEO for the past six years.

“[A] respected leader who has built an impressive track record of delivering results, both strategically and operationally, with deep involvement across all facets of late stage clinical research,” as described by Ramsey Frank, partner and cofounder of Amulet Capital Partners (backer of SynteractHCR), Powell brings with him more than 25 years of leadership experience in the biopharma industry.

Powell came on board with ERT last December as it acquired Exco InTouch, where he was president and COO. Both companies were focused on electronic clinical outcome assessments.

During his time at Exco Intouch, he managed the operations and development of technology in patient engagement, data capture and digital health. Prior to the clinical research tech firm, he was with another CRO giant, PRA Health Sciences, for over eight years, serving as EVP of clinical informatics and late-phase services.

As for his new job at SynteractHCR, Powell already has a plan, which very much involves his expertise in the digital and technology side of clinical research.

“Short-term, SynteractHCR will continue to build on the highly responsive services and successful growth we have seen to date, with even greater utilization of our international resources,” Powell told FierceCRO in an emailed interview. “In addition, we will look to augment our data capabilities; my first-hand operations experience in this area is an added strength we bring to the table.

“We bring an innovative mix of process and technology, with a focused global presence, to ensure we are leaders in new, often complex trial designs with effective delivery models. With the need to develop and evaluate quickly, our customers can access the change agents of the trial process we offer and this will ensure that SynteractHCR fills the voids left by the consolidation in the industry.”

The CRO industry has been shifting toward eClinical solutions to bring down cost, streamline clinical workflow and simplify clinical research management, a trend that sees the growth of clinical software providers like Medidata, five of whose products SynteractHCR is accredited to use.

By Angus Liu

Source: Fierce Biotech

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.